This topic is locked"Targeting NAMPT as a therapeutic strategy against stroke
Here, we review the direct evidence of NAMPT as a promising target against stroke from five potential therapeutic strategies, including NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product nicotinamide mononucleotide (NMN), and NMN precursors nicotinamide riboside and nicotinamide, and describe the relevant mechanisms and limitations, providing a promising choice for developing novel and effective therapeutic interventions against ischaemic and haemorrhagic stroke."
https://svn.bmj.com/content/4/2/83
svnbmj-2019-June-4-2-83-F1.medium.gif 36.78KB
0 downloads
"There are two ways to maintain the cellular NAD level in mammals: the de novo pathway from tryptophan and the salvage pathway from NAM, NR and NA with different catalysing enzymes.
NAMPT is the rate-limiting enzyme of NAD synthesis in the salvage pathway, thereby influencing NAD-dependent enzymes and regulating cellular metabolism, mitochondrial biogenesis and the adaptive response to inflammatory, oxidative, proteotoxic and genotoxic stresses.
Accumulating in-vitro and in-vivo studies indicate that NAMPT is a therapeutic target against stroke from five potential therapeutic strategies: NAMPT overexpression, recombinant NAMPT, NAMPT activators, NAMPT enzymatic product NMN, NMN precursors NR and NAM.
In ischaemic stroke, targeting NAMPT can confer neuroprotection via regulating mitochondrial biogenesis, activating SIRT1, inhibiting PARP1 activity and mimicking IPC. And, NAMPT related treatment exerts biological function in EPCs and NSCs to promote neovascularization and neurogenesis after ischaemic stroke."
Edited by Fredrik, 05 August 2019 - 07:53 AM.
